|
|
Blood, 15 November 2006, Vol. 108, No. 10, pp. 3611-3619.
Prepublished online as a Blood First Edition Paper on August 3, 2006; DOI 10.1182/blood-2006-04-017467.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients
Hong Xu,
Paula M. Chilton,
Michael K. Tanner,
Yiming Huang,
Carrie L. Schanie,
Mariano Dy-Liacco,
Jun Yan, and
Suzanne T. Ildstad
From the Institute for Cellular Therapeutics and the James Graham Brown Cancer Center, University of Louisville, Louisville, KY.
We evaluated the relative contribution of the humoral and cellular arms of the immune response to bone marrow cells transplanted into sensitized recipients. We report here for the first time that humoral immunity contributes predominantly to allosensitization. Although the major role for nonmyeloablative conditioning is to control alloreactive host T cells in nonsensitized recipients, strikingly, none of the strategies directed primarily at T-cell alloreactivity enhanced engraftment in sensitized mice. In evaluating the mechanism behind this barrier, we found that humoral immunity plays a critical role in the rejection of allogeneic marrow in sensitized recipients. Adoptive transfer of as little as 25 µL serum from sensitized mice abrogated engraftment in secondary naive recipients. With the use of µMT mice as recipients, we found that T-cell-mediated immunity plays a secondary but still significant role in allorejection. Targeting of T cells in sensitized B-cell-deficient µMT mice enhanced alloengraftment. Moreover, both T- and B-cell tolerance were achieved in sensitized recipients when allochimerism was established, as evidenced by the acceptance of second donor skin grafts and loss of circulating donor-specific Abs. These findings have important implications for the management of sensitized transplant recipients and for xenotransplantation in which B-cell reactivity is a predominant barrier.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Storb
B cells versus T cells as primary barrier to hematopoietic engraftment in allosensitized recipients
Blood,
January 29, 2009;
113(5):
1205 - 1205.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Xu, Y. Huang, P. M. Chilton, L.-R. Hussain, M. K. Tanner, J. Yan, and S. T. Ildstad
Strategic Nonmyeloablative Conditioning: CD154:CD40 Costimulatory Blockade at Primary Bone Marrow Transplantation Promotes Engraftment for Secondary Bone Marrow Transplantation after Engraftment Failure
J. Immunol.,
November 1, 2008;
181(9):
6616 - 6624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Shi, S. A. Fahs, D. A. Wilcox, E. L. Kuether, P. A. Morateck, N. Mareno, H. Weiler, and R. R. Montgomery
Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity
Blood,
October 1, 2008;
112(7):
2713 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Horne, J. M. Zimmerer, M. G. Fisher, K. E. Lunsford, G. Nadasdy, T. Nadasdy, N. van Rooijen, and G. L. Bumgardner
Critical Role of Effector Macrophages in Mediating CD4-Dependent Alloimmune Injury of Transplanted Liver Parenchymal Cells
J. Immunol.,
July 15, 2008;
181(2):
1224 - 1231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Xu, J. Yan, Y. Huang, P. M. Chilton, C. Ding, C. L. Schanie, L. Wang, and S. T. Ildstad
Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization
Blood,
March 15, 2008;
111(6):
3266 - 3275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Fowler
B-ware of allosensitized graft rejection
Blood,
February 1, 2007;
109(3):
851 - 852.
[Full Text]
[PDF]
|
|
|
|
|
